Iovance Biotherapeutics Inc   (IOVA)
Other Ticker:  
Price: $16.7900 $0.88 5.531%
Day's High: $17.19 Week Perf: 1.14 %
Day's Low: $ 16.26 30 Day Perf: 117.21 %
Volume (M): 11,006 52 Wk High: $ 18.33
Volume (M$): $ 184,789 52 Wk Avg: $6.95
Open: $16.36 52 Wk Low: $3.21

 Market Capitalization (Millions $) 3,945
 Shares Outstanding (Millions) 235
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -444
 Cash Flow (TTM) (Millions $) -57
 Capital Exp. (TTM) (Millions $) 22

Iovance Biotherapeutics Inc
Iovance Biotherapeutics Inc is a biotechnology company that specializes in developing and commercializing life-saving cell therapies. They focus on the development of tumor-infiltrating lymphocyte (TIL) therapies, which involve the extraction of a patient's own immune cells, expanding and activating them in the lab, and then infusing them back into the patient to target and fight cancer cells.

The company's TIL therapies have shown promising results in clinical trials, particularly in patients with advanced melanoma. Iovance Biotherapeutics aims to provide personalized cancer treatments using TIL therapies as a potential alternative to traditional approaches like chemotherapy.

They have a dedicated team of scientists, researchers, and clinicians who work towards advancing their TIL therapies and expanding their pipeline to target different types of cancer. Additionally, the company collaborates with various academic and industry partners to leverage cutting-edge technology and expertise in their research and development efforts.

Iovance Biotherapeutics Inc operates globally and is committed to improving the lives of cancer patients by delivering innovative cell therapies that harness the power of the immune system to fight cancer.

   Company Address: 825 Industrial Road, Suite 400 San Carlos 94070 CA
   Company Phone Number: 260-7120   Stock Exchange / Ticker: NASDAQ IOVA


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Iovance Biotherapeutics Inc

Financial Challenges Amidst Innovation: Iovance Biotherapeutics Reports Revenue of $0.482 Million for Q4 2023

Iovance Biotherapeutics Inc, a leading biotechnology company, recently announced its financial results for the fourth quarter of 2023. The company reported revenue of $0.482 million for the quarter, with a net shortfall of $-116.379 million. This shortfall was larger than the $-105.319 million reported in the same quarter a year ago, indicating a significant increase in expenses for the company. Additionally, Iovance Biotherapeutics reported a net deficit of $-444.04 million for the fiscal year 2023, with total revenue reaching $1.19 million.
Despite these financial challenges, Iovance Biotherapeutics has made significant progress in advancing its novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for cancer patients. The company recently announced FDA approval for one of its therapies, demonstrating its commitment to innovation and improving patient outcomes.


Iovance Biotherapeutics, Inc.: Fostering Innovations in TIL Therapies for Cancer Patients

Published Tue, Feb 20 2024 11:31 AM UTC

In a recent press release, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a leading biotechnology company, announced the pricing of an underwritten offering of its common stock. This offering is expected to generate approximately $211 million in gross proceeds for Iovance. The funds raised will support the company's continued efforts in developing and delivering nov...


Iovance Biotherapeutics Bolsters Team and Shareholder Value Through Inducement Stock Options Grants

Published Fri, Feb 16 2024 10:31 PM UTC

Iovance Biotherapeutics Continues to Expand Team and Enhance Shareholder Value Through Inducement Stock Options Grants
SAN CARLOS, Calif., Feb. 16, 2024 - Iovance Biotherapeutics, a biotechnology company specializing in TIL therapies for cancer patients, recently announced inducement stock options grants to sixteen new non-executive employees. This move comes on the hee...

Product Service News

Iovance's AMTAGVI Wins FDA Approval, Unleashing the Power of T Cell Therapy Against Advanced Melanoma

Published Fri, Feb 16 2024 8:20 PM UTC

Iovance's AMTAGVI (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced MelanomaIn a groundbreaking development, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Iovance Biotherapeutics' AMTAGVI (lifileucel), making it the first FDA-approved T cell therapy for a solid tumor cancer. Specifically designed as a treatment option for adva...

Clinical Study

Revolutionizing the Fight Against Non-Small Cell Lung Cancer: Iovance Biotherapeutics Unveils Clinical Trial Updates for Groundbreaking LN-145

Published Wed, Dec 27 2023 12:01 PM UTC

The arena of cancer research and treatment is continually evolving with the tireless efforts and innovation of biotechnology firms globally. One such entity leading the charge is Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). The biotechnology company, rooted firmly in the development and deployment of pioneering polyclonal tumor-infiltrating lymphocyte (TIL) therapies for ca...


Iovance Biotherapeutics Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Iovance Biotherapeutics Inc does not provide revenue guidance.

Earnings Outlook
Iovance Biotherapeutics Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com